StocksMedium•6 November 2026•
1 min read
Anika Revenue Rises 10% in Q3 as Company Lifts Full-Year 2026 Guidance
Key Facts
1Anika's Q3 revenue increased 10% year-over-year, driven by 17% growth in commercial channels.
2The company raised the lower end of its full-year 2026 revenue guidance and increased its adjusted EBITDA guidance.
3The company secured a new 10-year Hyvisc partnership with enhanced economics.
Anika Therapeutics revenue increased 10% year-over-year to $30.6 million in the third quarter of 2026. The company stated in a GlobeNewswire release that performance was driven by 17% growth in commercial channels, including a more than 30% increase in Integrity revenue.
The company raised the lower end of its full-year 2026 revenue guidance and increased its adjusted EBITDA targets. Anika also secured a new 10-year partnership for its Hyvisc product, while ANIK stock closed at $19.33 on November 5, 2026.